Suppr超能文献

病因不明的血细胞减少症患者中,自主T细胞增殖频率高,符合T细胞大颗粒淋巴细胞白血病。

High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology.

作者信息

Bektas Ozlen, Uner Aysegul, Aydin Seda Muruvvet, Eliacik Eylem, Uz Burak, Işık Ayse, Haznedaroğlu Ibrahim Celalettin, Goker Hakan, Sayinalp Nilgun, Aksu Salih, Demiroglu Halûk, Ozcebe Osman Ilhami, Buyukasik Yahya

机构信息

Department of Hematology, Faculty of Medicine, Hacettepe University, 06100, Sihhiye, Ankara, Turkey.

出版信息

Int J Hematol. 2015 Aug;102(2):211-7. doi: 10.1007/s12185-015-1816-y. Epub 2015 May 26.

Abstract

Large granular lymphocytic leukemia/lymphoproliferative disorder (LGL-L/LPD) is a heterogeneous neoplastic disease of large granular lymphocytes and is a well-known cause of cytopenias. We aimed to reveal the incidence of LGL-L/LPD in patients with cytopenia(s) of unknown etiology (CUE). Twenty-eight patients with CUE were investigated for LGL-L/LPD. T-cell LGL leukemia (LGL-L) was diagnosed in 12 (42.9 %) patients. The frequencies of LGL-L in patients who had anemia, neutropenia, and thrombocytopenia were 9/14 (64.2 %), 11/23 (47.8 %), and 3/10 (30 %), respectively. Seventeen of the 28 patients met the criteria of idiopathic cytopenia of undetermined significance (ICUS), and LGL-L was found in six (35.3 %) of them. We conclude that LGL-L is a rather common disease in patients with CUE and ICUS. It should be considered in this patient group and investigated thoroughly.

摘要

大颗粒淋巴细胞白血病/淋巴细胞增殖性疾病(LGL-L/LPD)是一种大颗粒淋巴细胞的异质性肿瘤性疾病,是血细胞减少症的一个众所周知的病因。我们旨在揭示病因不明的血细胞减少症(CUE)患者中LGL-L/LPD的发病率。对28例CUE患者进行了LGL-L/LPD调查。12例(42.9%)患者被诊断为T细胞大颗粒淋巴细胞白血病(LGL-L)。贫血、中性粒细胞减少和血小板减少患者中LGL-L的发生率分别为9/14(64.2%)、11/23(47.8%)和3/10(30%)。28例患者中有17例符合意义未明的特发性血细胞减少症(ICUS)标准,其中6例(35.3%)发现有LGL-L。我们得出结论,LGL-L在CUE和ICUS患者中是一种相当常见的疾病。在该患者群体中应予以考虑并进行彻底调查。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验